Home/Biomea Fusion/Ralph DeFronzo, M.D.

RD

Ralph DeFronzo, M.D.

Key Opinion Leader / Scientific Advisor

Therapeutic Areas

Diabetes Obesity

Biomea Fusion Pipeline

Drug	Indication	Phase
Icovamenib (BMF-219)	Type 2 Diabetes (Insulin-Deficient)	Phase 2
BMF-650	Obesity / Metabolic Disease	Preclinical

Leadership Team at Biomea Fusion

Mick Hitchcock, Ph.D.

Interim Chief Executive Officer and Board Member

Juan Pablo Frías, M.D.

Chief Medical Officer

View full Biomea Fusion profile